MISTI READY: Open Payments
NPI 1750696498 · FLOWOOD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$465 in 27 payments from 10 companies in 2025. Trend: 2023 $2,536 · 2024 $721 · 2025 $465
Food & beverage: $465
| Company | Payments | Amount |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 11 | $152 |
| QOL Medical, LLC | 3 | $69 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $59 |
| Ipsen Biopharmaceuticals, Inc | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| GENZYME CORPORATION | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Intercept Pharmaceuticals, Inc. | 1 | $19 |
| Novo Nordisk Inc | 1 | $17 |
Products named: VOQUEZNA, Sucraid, XIFAXAN, IQIRVO, DUPIXENT, VOWST, ENTYVIO, OCALIVA.
Industry payments across MS — which companies pay providers there.
